Modeling and Simulation in the Development of Cardiovascular Agents
作者： Diane R. Mould , Bill Frame , Timothy Taylor
DOI: 10.1007/978-1-4419-7415-0_10
关键词:
摘要: Cardiovascular pharmacology encompasses a wide range of diseases. With most agents in this therapeutic area, there are specific targets for biomarkers such as systolic blood pressure or LDL cholesterol levels that need to be met ensure adequate clinical response patients. Overdoses these may associated with toxicity. Modeling and simulation have proven valuable tools target adjust doses Because cardiovascular adaptively dosed based on individual response, the dose adjustment strategy must implemented model evaluation simulation. This chapter reviews areas treatment hypercholesterolemia, stroke hypertension, applications modeling disease states.
springer.com
sci-hub.st 参考文章(59)
Sylvie Chabaud, Pascal Girard, Patrice Nony, Jean-Pierre Boissel, None, Clinical Trial Simulation Using Therapeutic Effect Modeling: Application to Ivabradine Efficacy in Patients with Angina Pectoris Journal of Pharmacokinetics and Pharmacodynamics. ,vol. 29, pp. 339- 363 ,(2002) , 10.1023/A:1020953107162
Bruce Green, Stephen B. Duffull, Development of a dosing strategy for enoxaparin in obese patients British Journal of Clinical Pharmacology. ,vol. 56, pp. 96- 103 ,(2003) , 10.1046/J.1365-2125.2003.01849.X
Ene I. Ette, Paul J. Williams, Pharmacometrics : the science of quantitative pharmacology John Wiley & Sons. ,(2007)
Diane R. Mould, Developing Models of Disease Progression John Wiley & Sons, Inc.. pp. 547- 581 ,(2006) , 10.1002/9780470087978.CH21
Donald B. Hunninghake, HMG CoA reductase inhibitors Current Opinion in Lipidology. ,vol. 3, pp. 22- 28 ,(1992) , 10.1097/00041433-199202000-00005
R. BULLOCK, A. ZAUNER, J. S. MYSEROS, A. MARMAROU, J. J. WOODWARD, H. F. YOUNG, Evidence for prolonged release of excitatory amino acids in severe human head trauma. Relationship to clinical events. Annals of the New York Academy of Sciences. ,vol. 765, pp. 290- 297 ,(1995) , 10.1111/J.1749-6632.1995.TB16586.X
Lena E Friberg, Mats O Karlsson, Mechanistic models for myelosuppression. Investigational New Drugs. ,vol. 21, pp. 183- 194 ,(2003) , 10.1023/A:1023573429626
David Williams, John Feely, Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors Clinical Pharmacokinectics. ,vol. 41, pp. 343- 370 ,(2002) , 10.2165/00003088-200241050-00003
Gregory B Hammer, Susan T Verghese, David R Drover, Myron Yaster, Joseph R Tobin, Pharmacokinetics and pharmacodynamics of fenoldopam mesylate for blood pressure control in pediatric patients BMC Anesthesiology. ,vol. 8, pp. 6- 6 ,(2008) , 10.1186/1471-2253-8-6
R. Bullock, A. Zauner, J. Woodward, H.F. Young, Massive Persistent Release of Excitatory Amino Acids Following Human Occlusive Stroke Stroke. ,vol. 26, pp. 2187- 2189 ,(1995) , 10.1161/01.STR.26.11.2187